FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Capricor’s BLA for Deramiocel received Priority Review in March 2025
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
It is intended for contrast enhancement in MRI scans
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Subscribe To Our Newsletter & Stay Updated